Lantheus Holdings Inc (LNTH)vsViatris Inc (VTRS)
LNTH
Lantheus Holdings Inc
$100.98
-1.79%
HEALTHCARE · Cap: $6.80B
VTRS
Viatris Inc
$15.88
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 842% more annual revenue ($14.56B vs $1.55B). LNTH leads profitability with a 18.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.14. LNTH earns a higher WallStSmart Score of 67/100 (B-).
LNTH
Strong Buy67
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.1%
Fair Value
$65.91
Current Price
$100.98
$35.07 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 76.5% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Strong operational efficiency at 21.6%
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
1.2% revenue growth
Weak financial health signals
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LNTH
The strongest argument for LNTH centers on EPS Growth, Debt/Equity, Return on Equity. Profitability is solid with margins at 18.0% and operating margin at 21.6%. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : LNTH
The primary concerns for LNTH are Revenue Growth, Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LNTH profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
VTRS is growing revenue faster at 8.1% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
LNTH scores higher overall (67/100 vs 50/100), backed by strong 18.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lantheus Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?